Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092323 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
A Phase 2 study of Soft Tissue Sarcoma of the Extremity, sponsored by Sarcoma Alliance for Research through Collaboration.
- Active
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 20
- Study locations
NCT03092323 is a Phase 2 study of Soft Tissue Sarcoma of the Extremity that is active but no longer recruiting, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 126 participants. The trial reports 20 study locations across 18 states.
The verdict
NCT03092323, a Phase 2 study of Soft Tissue Sarcoma of the Extremity, is active but no longer recruiting, sponsored by Sarcoma Alliance for Research through Collaboration.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (20)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania- Abramson Cancer Center - Philadelphia
- University of Pittsburgh (UPMC Hillman Cancer Center) - Pittsburgh
California
- University of California Los Angeles - Los Angeles
Florida
- Mayo Clinic- Florida - Jacksonville
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins University - Baltimore
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03092323
The ClinicalTrials.gov registry entry for NCT03092323 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Soft Tissue Sarcoma of the Extremity appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03092323 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT03092323 about?
NCT03092323 is a clinical study titled "A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity". This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one...
What is the current status of trial NCT03092323?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2017-07-19. Estimated completion is 2028-09-01.
What conditions does trial NCT03092323 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma of the Extremity.
What interventions are being tested in trial NCT03092323?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03092323?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03092323 being conducted?
This trial has 20 study locations across California, Florida, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.